(CELG) Celgene Analyst Maintains Neutral Recommendation
We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development and commercialization of drugs in the areas of cancer and immune/inflammatory diseases. The company’s key growth engine is Revlimid, currently approved for myelodysplastic syndrome (MDS) and second-line [...] (CELG) Celgene Analyst Maintains Neutral Recommendation
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here